The comparative pharmacokinetic (PK), safety, and tolerability study for itraconazole in healthy adults for Gorlin Syndrome is progressing in line with planned timelines and budget. The study is a three-way crossover design against a reference listed drug, conducted in Malaysia in collaboration with Avior Bio, Inc. Period 2 of the study is scheduled for April 10, 2026, and Period 3 for April 24, 2026. Plasma samples are expected to be shipped for bioanalysis around May 1, 2026, with bioanalytical work requiring approximately two weeks, followed by two additional weeks for statistical analysis. The company expects to receive top-line comparative PK and relative bioavailability results in advance of the full Clinical Study Report. This PK study is expected to be the final clinical study required prior to submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration for the Basal Cell Carcinoma Nevus Syndrome (BCCNS) program. Inhibitor Therapeutics is developing a proprietary amorphous formulation of itraconazole, designed to enhance solubility, dissolution, and improve intestinal absorption, addressing limitations of the conventional crystalline form. A new global patent application is being prepared for this proprietary formulation, which, if granted, would be owned by Inhibitor Therapeutics without ongoing royalty obligations and is expected to strengthen the company's intellectual property estate.